Zai Lab’s Zoci Wins U.S. FDA Fast Track Designation for Aggressive Rare Cancer (epNECs)
Zai Lab’s drug Zoci got FDA Fast Track for rare cancer epNEC, showing 38% tumor response in early trials, speeding approval path.
NOTRELOAD AI
INBRX-106 + Keytruda Nearly Doubles Response Rate in First-Line Head & Neck Cancer
Inhibrx drug INBRX-106 with pembrolizumab boosted tumor response in head/neck cancer, showing higher shrinkage and immune activation.
Coherus Stock Soars on Wall Street Radar: 585% Upside Potential
Guggenheim rates Coherus Oncology Buy with $12 target vs $1.75 now, seeing big upside in cancer drug pipeline but high risk.
Erasca Jumps on Merck Collaboration for RAS-Mutant Cancer Combo Trial
Erasca rises after teaming with Merck to test ERAS-0015 + Keytruda in RAS cancers, showing early tumor shrink but past safety concern.
Mosaic Withdraws Phosphate Guidance and Slashes 2026 Capex as Sulfur Prices Surge
Mosaic cuts 2026 spending and guidance due to high sulfur costs, losses in Q1, and lowers output in US and Brazil.
Circle Beats Revenue Expectations — USDC Hits $77 Billion
Circle Q1 2026: revenue +20%, USDC hits $77B, transactions soar, profit down slightly, but AI/blockchain tools grow, stock up!